Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Kanamori, Heiwa  [Clear All Filters]
2024
Tachibana T, Miyazaki T, Matsumura A, Hagihara M, Tanaka M, Koyama S, Ogusa E, Aoki J, Nakajima Y, Takahashi H, et al. Investigation of biomarkers to predict outcomes in allogeneic hematopoietic stem cell transplantation. Cytotherapy. 2024.
Miyazaki T, Tachibana T, Suzuki T, Izumi A, Fujimaki K, Sato S, Tamai Y, Michishita Y, Suzuki T, Ishii R, et al. Pretransplant inflammatory and nutritional status in elderly allogeneic hematopoietic stem cell transplantation: prognostic value of C-reactive protein-to-albumin ratio. Transplant Cell Ther. 2024.
2023
Nukui J, Tachibana T, Miyazaki T, Tanaka M, Matsumoto K, Ishii Y, Numata A, Nakajima Y, Matsumura A, Suzuki T, et al. Clinical significance of total nucleated cell count in bone marrow of patients with acute lymphoblastic leukemia who underwent allogeneic hematopoietic stem cell transplantation. Int J Hematol. 2023.
Harada K, Onizuka M, Mori T, Shimizu H, Seo S, Aotsuka N, Takeda Y, Sekiya N, Kusuda M, Fujihara S, et al. Prognostic factors for the development of lower respiratory tract infection after influenza virus infection in allogeneic hematopoietic stem cell transplantation recipients: A KSGCT Multicenter Analysis. Int J Infect Dis. 2023.
2021
Harada I, Sasaki H, Murakami K, Nishiyama A, Nakabayashi J, Ichino M, Miyazaki T, Kumagai K, Matsumoto K, Hagihara M, et al. Compromised anti-tumor-immune features of myeloid cell components in chronic myeloid leukemia patients. Sci Rep. 2021;11(1):18046.
2020
Kawashima N, Ishikawa Y, Atsuta Y, Sawa M, Ozawa Y, Hayashi M, Kohno A, Tomita A, Maeda T, Sakaida E, et al. Allogeneic HSCT at the first remission for younger adults with FLT3-ITD AML: The JALSG AML209-FLT3-SCT Study. Cancer Sci. 2020.
Ikeda K, Ohto H, Yamada-Fujiwara M, Okuyama Y, Fujiwara S-I, Muroi K, Mori T, Kasama K, Kanamori H, Iseki T, et al. Hematopoietic cell infusion-related adverse events in pediatric/small recipients in a prospective/multicenter study. Transfusion. 2020.
2019
Ando T, Suzuki T, Ishiyama Y, Koyama S, Tachibana T, Tanaka M, Kanamori H, Nakajima H. Impact of Cytomegalovirus Reactivation and Natural Killer Reconstitution on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation: A Single Center Analysis. Biol Blood Marrow Transplant. 2019.
Ohwada C, Sakaida E, Igarashi A, Kobayashi T, Doki N, Mori T, Kato J, Koda Y, Kanamori H, Tanaka M, et al. A Prospective, Longitudinal Observation of the Incidence, Treatment, and Survival of Late Acute and Chronic Graft-versus-host disease by National Institutes of Health Criteria in a Japanese cohort. Biol Blood Marrow Transplant. 2019.
2018
Akahoshi Y, Mizuta S, Shimizu H, Uchida N, Fukuda T, Kanamori H, Onizuka M, Ozawa Y, Ohashi K, Ohta S, et al. Additional cytogenetic abnormalities with Philadelphia chromosome-positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Transplant. 2018.
Harada K, Yanada M, Machida S, Kanamori H, Onizuka M, Ozawa Y, Kobayashi H, Sawa M, Katayama Y, Ohashi K, et al. Prognostic impact of melphalan dose and total body irradiation use in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation with reduced-intensity conditioning. Leuk Lymphoma. 2018:1-10.
2016
Ishiyama K, Yamaguchi T, Eto T, Ohashi K, Uchida N, Kanamori H, Fukuda T, Miyamura K, Inoue Y, Taguchi J, et al. Acute megakaryoblastic leukemia, unlike acute erythroid leukemia, predicts an unfavorable outcome after allogeneic HSCT. Leuk Res. 2016;47:47-53.